🇺🇸 FDA

Intelligence · Clinical Pipeline

Anaxis Pharma Pipeline

All ClinicalTrials.gov programs at Anaxis Pharma — phase, modality, and trial IDs.

Programs
223

Quick answer

Anaxis Pharma has 223 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. (+)-α-DIHYDROTETRABENAZINE

    Lacuna Pharma Pty Ltd

    Tardive dyskinesia

    phase 2 small molecule active

    1 trial

  2. (+)-α-DIHYDROTETRABENAZINE

    Lacuna Pharma Pty Ltd

    tardive dyskinesia

    phase 2 small molecule active

    1 trial

  3. (+)-α-DIHYDROTETRABENAZINE, ADE513 placebo

    Lacuna Pharma Pty Ltd

    Tardive dyskinesia

    phase 2 small molecule active

    1 trial

  4. -

    Lacuna Pharma Pty Ltd

    Myocardial Infarction, Acute Heart Failure, Left Sided

    phase 2 small molecule active

    1 trial

  5. -, -, CIMETIDINE , ROXATIDINE , FAMOTIDINE, COMBINATIONS, PARACETAMOL , RANITIDINE , NIZATIDINE , SKB264, FAMOTIDINE , -

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

    phase 2 small molecule active

    1 trial

  6. -, -, ROXATIDINE , RANITIDINE , OSIMERTINIB , NIZATIDINE , SKB264, CIMETIDINE , FAMOTIDINE, COMBINATIONS, FAMOTIDINE , CARBOPLATIN , PARACETAMOL , PEMBROLIZUMAB , OSIMERTINIB, -

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. 0.9% Sodium Chloride for Injection (Fresenius Kab) sourced locally by sites, AP-101

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  8. A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced SST2-positive neuroendocrine neoplasms in adults

    phase 2 other active

    1 trial

  9. A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis

    Lacuna Pharma Pty Ltd

    Primary Hyperoxaluria

    phase 2 other active

    1 trial

  10. A Phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of Azeliragon combined with conventional concurrent radiation and temozolomide in patients with newly diagnosed glioblastoma.

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 2 other active

    1 trial

  11. ABO-102, ABO-102, ABO-102

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type IIIA

    phase 2 small molecule active

    1 trial

  12. AC102-Suspension 12 mg/ml, placebo gel, Placebo matching Prednisolone, Prednisolon 10 mg GALEN®

    Lacuna Pharma Pty Ltd

    Idiopathic Sudden Sensorineural Hearing Loss

    phase 2 small molecule active

    1 trial

  13. ACT-1004-1239 matching placebo

    Lacuna Pharma Pty Ltd

    Progressive multiple sclerosis (MS)

    phase 2 small molecule active

    1 trial

  14. ADX-038

    Lacuna Pharma Pty Ltd

    Complement-Mediated Kidney Disease

    phase 2 small molecule active

    1 trial

  15. ADX-038, Sodio cloruro Galenica Senese 0,9% solvente per uso parenterale

    Lacuna Pharma Pty Ltd

    Geographic atrophy secondary to age-related macular degeneration

    phase 2 small molecule active

    1 trial

  16. AL8326

    Lacuna Pharma Pty Ltd

    Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.

    phase 2 small molecule active

    1 trial

  17. AL8326

    Lacuna Pharma Pty Ltd

    - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.

    phase 2 small molecule active

    1 trial

  18. ALDARA 5% cream, Keramod® gel

    Lacuna Pharma Pty Ltd

    Actinic keratosis

    phase 2 small molecule active

    1 trial

  19. ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PDC*lung01, PDC*lung01

    Lacuna Pharma Pty Ltd

    Non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  20. AN OPEN-LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE SAFETY AND EFFICACY IN PARTICIPANTS TREATED WITH CRN04894

    Lacuna Pharma Pty Ltd

    CONGENITAL ADRENAL HYPERPLASIA

    phase 2 other active

    1 trial

  21. AP02 High, AP02 Low, AP02 Placebo

    Lacuna Pharma Pty Ltd

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  22. AP1189 Tablet, AP1189 Tablet, AP1189 Tablet, Matching Placebo (tablets), Methotrexat-Ebewe, 2,5 mg, tabletki

    Lacuna Pharma Pty Ltd

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  23. AP31969, AP31969, The placebo tablets contain the same excipient as in the active IMP, but without AP31969. All tablet strengths containing AP31969 as well as placebo tablets are visually identical., AP31969, AP31969

    Lacuna Pharma Pty Ltd

    Atrial fibrillation

    phase 2 small molecule active

    1 trial

  24. AP707, Placebo

    Lacuna Pharma Pty Ltd

    Borderline personality disorder

    phase 2 small molecule active

    1 trial

  25. ART0380, ART0380, GEMCITABINE , ART0380, IRINOTECAN , ART0380

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Solid Tumours

    phase 2 small molecule active

    1 trial

  26. ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 2 small molecule active

    1 trial

  27. ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule active

    1 trial

  28. Actrapid 100 international units/ml solution for injection in vial, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, SODIUM CHLORIDE, Natriumklorid Fresenius Kabi 9 mg/ml, spädningsvätska för parenteral användning, Albumin Baxalta 200 g/l infusionsvätska, lösning, Glucos Fresenius Kabi 200 mg/ml infusionsvätska, lösning, A24110He

    Lacuna Pharma Pty Ltd

    Moderate to severe hypertriglyceridemia

    phase 2 small molecule active

    1 trial

  29. An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies

    Lacuna Pharma Pty Ltd

    Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy

    phase 2 other active

    1 trial

  30. An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes

    Lacuna Pharma Pty Ltd

    transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes

    phase 2 other active

    1 trial

  31. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Idiopathic membranous nephropathy and severe proteinuria

    phase 2 small molecule active

    1 trial

  32. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica

    phase 2 small molecule active

    1 trial

  33. Atropine Sulfate 0.025% Eye Drops, solution in single-dose container, Atropine Sulfate 0.005% Eye Drops, solution in single-dose container, Placebo Atropine Sulfate Eye Drops, solution in single-dose container, Atropine Sulfate 0.01% Eye Drops, solution in single-dose container, Atropine Sulfate 0.05% Eye Drops, solution in single-dose container

    Lacuna Pharma Pty Ltd

    Myopia progression in children

    phase 2 small molecule active

    1 trial

  34. BCX17725

    Lacuna Pharma Pty Ltd

    Netherton Syndrome

    phase 2 small molecule active

    1 trial

  35. BNT116, LIBTAYO 350 mg concentrate for solution for infusion.

    Lacuna Pharma Pty Ltd

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  36. BRONCHO-VAXOM Children Capsules placebo, BRONCHO-VAXOM, 3,5mg, kapsułki

    Lacuna Pharma Pty Ltd

    Recurrent wheezing

    phase 2 small molecule active

    1 trial

  37. BW-20805 Injection

    Lacuna Pharma Pty Ltd

    Hereditary Angioedema

    phase 2 small molecule active

    1 trial

  38. Bepranemab, Placebo matching and without active substance, Neuraceq 300 MBq/mL solution for injection, (18F) GTP1

    Lacuna Pharma Pty Ltd

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  39. Bexmarilimab

    Lacuna Pharma Pty Ltd

    Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  40. CARBOPLATIN , PACLITAXEL , NP137, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Patiens with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.

    phase 2 small molecule active

    1 trial

  41. CND261

    Lacuna Pharma Pty Ltd

    Active, treatment refractory, ANCA-IgG-positive associated vasculitis

    phase 2 small molecule active

    1 trial

  42. CRD-4730, CRD-4730 matching placebo

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia

    phase 2 small molecule active

    1 trial

  43. CRD-4730, Encapsulation of microcrystalline cellulose into HPMC capsules to match the CRD-4730 active capsules in appearance

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

    phase 2 small molecule active

    1 trial

  44. CX11, Placebo to cx11 40 mg, CX11, Placebo to cx11 80 mg

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  45. Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory marginal zone lymphoma

    phase 2 small molecule active

    1 trial

  46. Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules

    Lacuna Pharma Pty Ltd

    Waldenström Macroglobulinemia

    phase 2 small molecule active

    1 trial

  47. Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  48. Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Richter's Syndrome, Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Anaxis Pharma have?

223 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.